了解MASH:根据TARGET-NASH数据库中的疾病严重程度对进展和临床结果的检查
1Novo Nordisk Inc., 800 Scudders Mill Rd, Plainsboro, NJ, 08536, USA.
Advances in therapy
|December 31, 2024
概括
代谢功能障碍相关的脂肪肝炎 (MASH) 进展到严重的结局,包括死亡率,与晚期纤维化和肝硬化有显著联系. 早期识别和管理MASH对于缓解疾病进展和并发症至关重要.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
背景情况:
- 代谢功能障碍相关的脂肪肝炎 (MASH) 是一种与肥胖和2型糖尿病 (T2D) 等心脏代谢风险因素相关的渐进性肝病.
- 由于MASH的患病率越来越高,因此需要对其进展及其相关结果有更深入的了解.
- 这项研究评估了基于疾病严重程度的MASH进展和并发症.
研究的目的:
- 根据疾病严重程度,评估MASH相关并发症的发生率,在患有非肝硬化MASH或MASH肝硬化的患者中.
- 确定与MASH进展相关的人口和临床特征.
- 评估非侵入性测试 (NIT) 与活检确定纤维化病阶段的协调性.
主要方法:
- 对TARGET-NASH队列的分析,包括美国学术和社区网站上MASH的成年人.
- 根据纤维化或肝硬化阶段对患者进行分层,以评估疾病的严重程度.
- 评估进展到MASH相关的结果:全因死亡率,肝硬化和肝移植.
主要成果:
- 随着疾病严重程度的增加,全因死亡率从纤维化阶段0-1 (F0-F1) 的0.14/100人月 (PM) 增加到非补偿性肝硬化中的4.62/100PM.
- 与F0-F1.0相比,患有F3和F2纤维化患者的肝硬化进展风险明显更高.
- 心脏代谢并发症,包括T2D (67.9%) 和高血压 (73.9%),在进展到MASH相关结局的患者中很普遍.
- 振动控制的过渡性弹性显微镜显示与活检确定的纤维化阶段比FIB-4指数更好.
结论:
- 更高的纤维化阶段和肝硬化显著与MASH患者全因死亡率的增加有关.
- 像T2D和高血压这样的心脏代谢并发症在经历MASH进展的患者中很常见.
- 早期识别和管理MASH对于减少疾病进展和肝脏相关并发症至关重要.
更多相关视频
04:14Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
Published on: April 16, 2019
11.9K
06:49A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS
Published on: October 6, 2015
19.5K
相关概念视频
01:22Nursing Diagnosis
2.6K
Following assessment, a nursing diagnosis is the next step in the nursing process. It begins after the nurse has collected and recorded the patient data. The purpose of diagnosing is to identify how the client responds to actual or potential health processes, identify factors that bestow or that cause health problems, the etiologies, and identify resources or strengths the individual, group, or community can draw on to prevent or resolve problems.
The nursing diagnosis focuses on evidence-based...
The nursing diagnosis focuses on evidence-based...
2.6K
01:20Comparing the Survival Analysis of Two or More Groups
149
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
149
01:15Nursing Evaluation
3.2K
The evaluation stage signals the end of the nursing process. The nurse gathers evaluative data to assess whether or not the patient has attained the expected results. Whereas the nurse collects data in the nursing assessment to identify the patient's health concerns, the evaluation stage data determines if the indicated health issues are resolved. Evaluative data collection includes two sections: the data acquired to evaluate patient outcomes and the time criteria for data collection.
3.2K
01:21Cancer Survival Analysis
328
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328
01:24Kaplan-Meier Approach
94
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
94
02:07Tumor Progression
6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K